Structures of HIV-1 Env V1V2 with broadly neutralizing antibodies reveal commonalities that enable vaccine design

Nature Structural and Molecular Biology

Volumn 23, Issue 1, 2016, Pages 81-90

  Gorman, Jason ^a   Soto, Cinque ^a   Yang, Max M ^a   Davenport, Thaddeus M ^b   Guttman, Miklos ^b   Bailer, Robert T ^a   Chambers, Michael ^a   Chuang, Gwo Yu ^a   Dekosky, Brandon J ^a,c   Doria Rose, Nicole A ^a   Druz, Aliaksandr ^a   Ernandes, Michael J ^a   Georgiev, Ivelin S ^a   Jarosinski, Marissa C ^a   Joyce, M Gordon ^a   Lemmin, Thomas M ^d   Leung, Sherman ^a   Louder, Mark K ^a   McDaniel, Jonathan R ^c   Narpala, Sandeep ^a   Pancera, Marie ^a   Stuckey, Jonathan ^a   Wu, Xueling ^a   Yang, Yongping ^a   Zhang, Baoshan ^a   Zhou, Tongqing ^a   Mullikin, James C ^e   Baxa, Ulrich ^f   Georgiou, George ^c   McDermott, Adrian B ^a   Bonsignori, Mattia ^g   Haynes, Barton F ^g   Moore, Penny L ^h,i,j   Morris, Lynn ^h,i,j   Lee, Kelly K ^b   Shapiro, Lawrence ^a,k   Mascola, John R ^a   Kwong, Peter D ^a   more..

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c The University of Texas at Austin   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^f FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

^g DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES   (South Africa)

ⁱ UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^j UNIVERSITY OF KWAZULU NATAL   (South Africa)

^k Och Spine at New York Presbyterian Hospitals   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

GLYCAN DERIVATIVE; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; V1V2 ANTIBODY; VACCINE; VIRUS ENVELOPE PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; PROTEIN BINDING;

ANTIGEN ANTIBODY REACTION; ARTICLE; CRYSTAL STRUCTURE; DRUG DESIGN; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL; VIRUS ENVELOPE; VIRUS MORPHOLOGY; CELL LINE; CHEMISTRY; HUMAN; IMMUNOLOGY; MOLECULAR MODEL; PROTEIN CONFORMATION; X RAY CRYSTALLOGRAPHY;

AIDS VACCINES; ANTIBODIES, NEUTRALIZING; CELL LINE; CRYSTALLOGRAPHY, X-RAY; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV ANTIBODIES; HIV-1; HUMANS; MODELS, MOLECULAR; PROTEIN BINDING; PROTEIN CONFORMATION;

EID: 84954381077     PISSN: 15459993     EISSN: 15459985     Source Type: Journal    
DOI: 10.1038/nsmb.3144     Document Type: Article

References (70)

1. Hraber, P. et al. Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection. AIDS 28, 163-169 (2014).
2. Burton, D.R. et al. HIV vaccine design and the neutralizing antibody problem. Nat. Immunol. 5, 233-236 (2004).
3. Haynes, B.F., Kelsoe, G., Harrison, S.C., Kepler, T.B. B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study. Nat. Biotechnol. 30, 423-433 (2012).
4. Kwong, P.D., Mascola, J.R. Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies. Immunity 37, 412-425 (2012).
5. Jardine, J. et al. Rational HIV immunogen design to target specific germline B cell receptors. Science 340, 711-716 (2013).
6. Wu, X. et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329, 856-861 (2010).
7. Zhou, T. et al. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 329, 811-817 (2010).
8. Scheid, J.F. et al. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science 333, 1633-1637 (2011).
9. Wu, X. et al. Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science 333, 1593-1602 (2011).
10. Zhou, T. et al. Multidonor analysis reveals structural elements, genetic determinants, and maturation pathway for HIV-1 neutralization by VRC01-class antibodies. Immunity 39, 245-258 (2013).
11. Zhou, T. et al. Structural repertoire of HIV-1-neutralizing antibodies targeting the CD4 Supersite in 14 donors. Cell 161, 1280-1292 (2015).
12. Dosenovic, P. et al. Immunization for HIV-1 broadly neutralizing antibodies in human Ig knockin mice. Cell 161, 1505-1515 (2015).
13. Jardine, J.G. et al. HIV-1 vaccines: priming a broadly neutralizing antibody response to HIV-1 using a germline-targeting immunogen. Science 349, 156-161 (2015).
14. Kong, L. et al. Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120. Nat. Struct. Mol. Biol. 20, 796-803 (2013).
15. Bonsignori, M. et al. Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors. J. Virol. 85, 9998-10009 (2011).
16. Doria-Rose, N.A. et al. Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. Nature 509, 55-62 (2014).
17. Walker, L.M. et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326, 285-289 (2009).
18. Walker, L.M. et al. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 477, 466-470 (2011).
19. Sok, D. et al. Recombinant HIV envelope trimer selects for quaternary-dependent antibodies targeting the trimer apex. Proc. Natl. Acad. Sci. USA 111, 17624-17629 (2014).
20. Pancera, M. et al. Crystal structure of PG16 and chimeric dissection with somatically related PG9: structure-function analysis of two quaternary-specific antibodies that effectively neutralize HIV-1. J. Virol. 84, 8098-8110 (2010).
21. Pejchal, R. et al. Structure and function of broadly reactive antibody PG16 reveal an H3 subdomain that mediates potent neutralization of HIV-1. Proc. Natl. Acad. Sci. USA 107, 11483-11488 (2010).
22. McLellan, J.S. et al. Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature 480, 336-343 (2011).
23. Doria-Rose, N.A. et al. A short segment of the HIV-1 gp120 V1/V2 region is a major determinant of resistance to V1/V2 neutralizing antibodies. J. Virol. 86, 8319-8323 (2012).
24. Julien, J.P. et al. Asymmetric recognition of the HIV-1 trimer by broadly neutralizing antibody PG9. Proc. Natl. Acad. Sci. USA 110, 4351-4356 (2013).
25. Pancera, M. et al. N332-directed broadly neutralizing antibodies use diverse modes of HIV-1 recognition: inferences from heavy-light chain complementation of function. PLoS One 8, e55701 (2013).
26. Pancera, M. et al. Structural basis for diverse N-glycan recognition by HIV-1-neutralizing V1-V2-directed antibody PG16. Nat. Struct. Mol. Biol. 20, 804-813 (2013).
27. Sanders, R.W. et al. A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies. PLoS Pathog. 9, e1003618 (2013).
28. Ross, S.A., Sarisky, C.A., Su, A., Mayo, S.L. Designed protein G core variants fold to native-like structures: sequence selection by ORBIT tolerates variation in backbone specification. Protein Sci. 10, 450-454 (2001).
29. Fazi, B. et al. Unusual binding properties of the SH3 domain of the yeast actin-binding protein Abp1: structural and functional analysis. J. Biol. Chem. 277, 5290-5298 (2002).
30. McLellan, J.S. et al. Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. Science 340, 1113-1117 (2013).
31. Zhou, T. et al. Transplanting supersites of HIV-1 vulnerability. PLoS One 9, e99881 (2014).
32. Do Kwon, Y. et al. Crystal structure, conformational fixation and entry-related interactions of mature ligand-free HIV-1 Env. Nat. Struct. Mol. Biol. 22, 522-531 (2015).
33. Badger, J. et al. Structural analysis of a set of proteins resulting from a bacterial genomics project. Proteins 60, 787-796 (2005).
34. Tyndall, J.D. et al. Macrophage migration inhibitory factor covalently complexed with phenethyl isothiocyanate. Acta Crystallogr. Sect. F Struct. Biol. Cryst. Commun. 68, 999-1002 (2012).
35. Pancera, M. et al. Structure and immune recognition of trimeric pre-fusion HIV-1 Env. Nature 514, 455-461 (2014).
36. Pan, R., Gorny, M.K., Zolla-Pazner, S., Kong, X.P. The V1V2 region of HIV-1 gp120 forms a five-stranded beta barrel. J. Virol. 89, 8003-8010 (2015).
37. Briney, B.S., Willis, J.R., Crowe, J.E. Jr. Human peripheral blood antibodies with long HCDR3s are established primarily at original recombination using a limited subset of germline genes. PLoS One 7, e36750 (2012).
38. Briney, B.S., Willis, J.R., Hicar, M.D., Thomas, J.W. II., Crowe, J.E. Jr. Frequency and genetic characterization of V(DD)J recombinants in the human peripheral blood antibody repertoire. Immunology 137, 56-64 (2012).
39. Zhu, J. et al. Mining the antibodyome for HIV-1-neutralizing antibodies with next-generation sequencing and phylogenetic pairing of heavy/light chains. Proc. Natl. Acad. Sci. USA 110, 6470-6475 (2013).
40. Shi, B. et al. Comparative analysis of human and mouse immunoglobulin variable heavy regions from IMGT/LIGM-DB with IMGT/HighV-QUEST. Theor. Biol. Med. Model. 11, 30 (2014).
41. Liao, H.X. et al. Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2. Immunity 38, 176-186 (2013).
42. Munro, J.B. et al. Conformational dynamics of single HIV-1 envelope trimers on the surface of native virions. Science 346, 759-763 (2014).
43. Sanders, R.W. et al. HIV-1 vaccines: HIV-1 neutralizing antibodies induced by native-like envelope trimers. Science 349, aac4223 (2015).
44. Meffre, E. et al. Immunoglobulin heavy chain expression shapes the B cell receptor repertoire in human B cell development. J. Clin. Invest. 108, 879-886 (2001).
45. Bhiman, J.N. et al. Viral variants that initiate and drive maturation of V1V2-directed HIV-1 broadly neutralizing antibodies.. Nat. Med. 21, 1332-1336 (2015).
46. West, A.P. Jr., Diskin, R., Nussenzweig, M.C., Bjorkman, P.J. Structural basis for germ-line gene usage of a potent class of antibodies targeting the CD4-binding site of HIV-1 gp120. Proc. Natl. Acad. Sci. USA 109, E2083-E2090 (2012).
47. McGuire, A.T. et al. Engineering HIV envelope protein to activate germline B cell receptors of broadly neutralizing anti-CD4 binding site antibodies. J. Exp. Med. 210, 655-663 (2013).
48. Majeed, S. et al. Enhancing protein crystallization through precipitant synergy. Structure 11, 1061-1070 (2003).
49. Otwinowski, Z., Minor, W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 276, 307-326 (1997).
50. Zhou, T. et al. Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature 445, 732-737 (2007).
51. Calarese, D.A. et al. Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science 300, 2065-2071 (2003).
52. Doria-Rose, N.A. et al. A new member of the V1V2-directed CAP256-VRC26 lineage that shows increased breadth and exceptional potency. J. Virol. doi: 10.1128/JVI.01791-15 (14 October 2015).
53. Huang, J. et al. Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interface. Nature 515, 138-142 (2014).
54. Scheid, J.F. et al. Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature 458, 636-640 (2009).
55. Chen, L. et al. Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120. Science 326, 1123-1127 (2009).
56. Kwong, P.D. et al. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393, 648-659 (1998).
57. Killikelly, A. et al. Thermodynamic signatures of the antigen binding site of mAb 447-52D targeting the third variable region of HIV-1 gp120. Biochemistry 52, 6249-6257 (2013).
58. Dreyfus, C. et al. Highly conserved protective epitopes on influenza B viruses. Science 337, 1343-1348 (2012).
59. Montefiori, D.C. Measuring HIV neutralization in a luciferase reporter gene assay. Methods Mol. Biol. 485, 395-405 (2009).
60. Shu, Y. et al. Efficient protein boosting after plasmid DNA or recombinant adenovirus immunization with HIV-1 vaccine constructs. Vaccine 25, 1398-1408 (2007).
61. Mastronarde, D.N. Automated electron microscope tomography using robust prediction of specimen movements. J. Struct. Biol. 152, 36-51 (2005).
62. Tang, G. et al. EMAN2: an extensible image processing suite for electron microscopy. J. Struct. Biol. 157, 38-46 (2007).
63. Guttman, M. et al. CD4-induced activation in a soluble HIV-1 Env trimer. Structure 22, 974-984 (2014).
64. Xiang, Z., Honig, B. Extending the accuracy limits of prediction for side-chain conformations. J. Mol. Biol. 311, 421-430 (2001).
65. Petrey, D. et al. Using multiple structure alignments, fast model building, and energetic analysis in fold recognition and homology modeling. Proteins 53 (suppl. 6), 430-435 (2003).
66. Ye, J., Ma, N., Madden, T.L., Ostell, J.M. IgBLAST: an immunoglobulin variable domain sequence analysis tool. Nucleic Acids Res. 41, W34-W40 (2013).
67. Sievers, F., Higgins, D.G. Clustal omega. Curr. Protoc. Bioinformatics 48, 3.13.1-3.13.16 (2014).
68. Xiang, Z., Soto, C.S., Honig, B. Evaluating conformational free energies: the colony energy and its application to the problem of loop prediction. Proc. Natl. Acad. Sci. USA 99, 7432-7437 (2002).
69. Wriggers, W., Milligan, R.A., McCammon, J.A. Situs: A package for docking crystal structures into low-resolution maps from electron microscopy. J. Struct. Biol. 125, 185-195 (1999).
70. Phillips, J.C. et al. Scalable molecular dynamics with NAMD. J. Comput. Chem. 26, 1781-1802 (2005).